The Heart of England Trust is to introduce new procedures following the publication of a "shocking" report into breast cancer surgery.
A US news anchor who was encouraged to have a mammogram live on television by her producers discovered she had breast cancer from the test.
Hundreds of lives could be saved every year if breast cancer patients took their full five-year course of drugs, according to research.
A new drug for terminal breast cancer sufferers is "a lifesaver" for women who have had been having chemeo therapy for a long time, one patient told Daybreak.
Mani Coulter said Kadcyla reduced the cancer "immediately" and had "minimal" side effects because it was a targeted drug.
Plans to roll out a "revolutionary" breast cancer drug across the UK are "a huge step forward", according to health campaigners.
Kadcyla will be available on the cancer drugs fund, a move which will make "a significant difference" to breast cancer sufferers who have stopped responding to chemo, according to Dr Caitlin Palframan.
– Dr Caitlin Palframan Breakthrough Breast Cancer
Kadcyla has been shown to extend life by up to six months in HER2-positive secondary breast cancer patients, and with more manageable side effects than alternative drugs.
It has the potential to provide women with a better quality of life in their final months than existing treatments, which could make a significant difference.
A thousand women die from metastatic, or secondary, breast cancer every month in the UK and this treatment has the potential to provide some of them not only with additional time, but importantly, quality time to spend with their friends and families.
A breast cancer drug for women who have stopped responding to conventional medicine has been launched in the UK.
Kadcyla - also called T-DM1 - will be given to terminal patients who have stopped responding to more established medicines, like Herceptin and chemotherapy.
It is only suitable for patients with the defective Her2 gene and trial results have shown it can extend life by six months compared with treatment with two other drugs, lapatinib (Tyverb) and capecitabine (a type of chemotherapy).
Kadcyla is administered intravenously once every three weeks.
Breast Cancer Campaign's Mia Rosenblatt said: "Today's announcement that this revolutionary new drug is now available to patients with advanced HER2-positive breast cancer (around 20% of those with breast cancer), is really encouraging news.
"It has been shown to extend life by up to six months and have more manageable side effects than other existing treatments."
Eastender's Barbara Windsor, TV presenter Gloria Hunniford and Harry Potter actress Miriam Margoyles, have all thrown their support behind the new "Be Clear on Cancer" campaign.
Windsor, 76, who plays Peggy Mitchell in the popular soap said she met a lot of women affected by breast cancer when preparing for Peggy Mitchell’s diagnosis in EastEnders, which made her realise "just how important an early diagnosis is".
TV and radio presenter Gloria Hunniford is also backing the campaign targeted at women aged 70 and over following the loss of her daughter to the disease."I know firsthand, having lost my daughter Caron, the impact breast cancer can have on people’s lives," she said.
Margoyles, known for her role playing Professor Sprout in the Harry Potter film series, said: "I have always had big boobs and I want to hang on to them. My advice - be vigilant and get checked out if you’re concerned - it could save your breasts and your life."
One in 3 women diagnosed with breast cancer in England each year is aged 70 or over, new figures from Public Health England show, accounting for more than half of all breast cancer deaths annually.
Around 13,500 women aged 70 and over are diagnosed with breast cancer in England each year, yet survival rates are lower in this age group compared to younger women. Lack of awareness is believed to be one of the reasons for this, which a new campaign, "Be Clear on Cancer" aims to change.
Two thirds of women aged 70 and over (67%) wrongly think women of all ages are equally likely to get breast cancer, when in fact a woman’s risk of breast cancer increases with age.
Dr Yvonne Doyle, Regional Director at Public Health England said women over 70 are more likely to delay heading to their GP, which could ultimately affect their chance of survival.
"One in 3 women who get breast cancer are over 70 , so don’t assume you’re past it or dismiss any symptoms as a sign of ageing," she said.
– Dr Richard Clarkson from Cardiff University's European Cancer Stem Cell Research Institute
We showed that suppressing this gene reduced the spread of cancer by more than 80%.
Our next goal was to then find a way to suppress Bcl3 pharmacologically. Despite great improvements in therapy of early stage breast cancer, the current therapeutic options for patients with late stage metastatic disease are limited.
There is therefore a clear unmet clinical need to identify new drugs to reverse or at least to slow down disease progression.
An experimental drug that can virtually halt the deadly spread of breast cancer has been tested by scientists.
Researchers are now working with a biotechnology company to prepare the compound for patient trials.
The new research builds on previous studies of a gene called Bc13 that appears to play a critical role in the spread of breast cancer.
Scientists at Cardiff University conducted computer simulations to work out how Bc13 functioned and then blocked it.
In tests on mice, the researchers first deleted the gene and then explored ways of inhibiting it with a drug.They found the right candidate compound by screening a library of chemicals until one was found that could target Bc13.
When mice with metastatic breast cancer were treated with the compound, the spread of tumours to the lungs and other parts of the body was dramatically reduced.
Women with breast cancer were seriously harmed and were victims of "weak and indecisive leadership from senior managers" at a hospital trust in the West Midlands, a damning report has concluded.
A review into what happened at Solihull Hospital - part of the Heart of England NHS Trust - found a "tragic story" that is also a story of "secrecy and containment".
Lawyer Sir Ian Kennedy, who led the review, said breast surgeon Ian Paterson, who has been suspended by the General Medical Council, was allowed to carry on operating on women for several years despite a series of concerns raised about him by other medical staff.
Up to 400 women are thought to be suing the trust and a private firm for failing to take action over the claims.
The review found that some of the women were exposed to a risk of cancer coming back after Mr Paterson performed only partial mastectomies.
In January a task force will be set up to address the recommendations in Sir Ian Kennedy's review into unnecessary and incomplete breast cancer operations at the Heart of England Trust. The Trust says it is aiming to implement the recommendations within six months.
It says it has recalled all of Ian Paterson’s mastectomy patients and is continuing to follow-up those requiring additional review. It says this this will be for 15 years - a longer period than normal
12 experts have now been asked to conduct a wider review in to all the surgeon's patients.